Thor Advisors’s AbbVie ABBV Stock Holding History

Thor Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$21K	Buy	+271	New	+$23.1K	1.1%	2

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Thor Advisors's ABBV Position: Q1 2020 in Review

Thor Advisors opened a new position in AbbVie (ABBV) in Q1 2020: 271 shares worth $21K. The stake represents 1.1% of the portfolio and ranks #2 among its holdings.

2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

Thor Advisors held 271 shares of AbbVie worth $21K as of Q1 2020.
AbbVie was a new Thor Advisors position in Q1 2020.
AbbVie made up 1.1% of Thor Advisors's portfolio in Q1 2020, its #2 holding.
2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Thor Advisors's 13F filing for Q1 2020, filed 18 May 2020.